A recent study from the IRIBHM, Brussels B-1070 shows that “SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.” This study was published in the July 10 2014 Nature by Boumahdi S and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anti-cancer stem cell therapeutics for skin tumors: BMP4 inhibits tumor initiation and stemness via down regulation of Sox2. This study suggests that BMP4, by decreasing the expression of Sox2 in squamous carcinoma cells, it may inhibit the progression of skin tumors. Together, this study suggests that pharmacological formulations encompassing“BMP4 activators” may be used to treat skin tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Anti-cancer stem cell therapeutics for skin tumors: BMP4 inhibits tumor initiation and stemness via down regulation of Sox2, 04/September/2014, 11.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.orgCourtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
